Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 3Phase 1 2Phase NA 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Gestational Trophoblastic Disease 1Esophageal Squamous Cell Carcinoma 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Radiotherapy 8camrelizumab 3Drug Therapy 3Cisplatin 3sintilimab 2Paclitaxel 2Neoadjuvant Therapy 2toripalimab 1tislelizumab 1pembrolizumab 1durvalumab 1anlotinib 1Surgical Procedures, Operative 1Radiofrequency Ablation 1Radiation 1Poly(ADP-ribose) Polymerase Inhibitors 1Observation 1Narrow Band Imaging 1Magnetic Resonance Spectroscopy 1Laparoscopy 1Immune Checkpoint Inhibitors 1Gene Expression Profiling 1Fluorouracil 1Fluorodeoxyglucose F18 1Esophagectomy 1Endoscopy, Digestive System 1Docetaxel 1Consolidation Chemotherapy 1Chemoradiotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Esophageal Squamous Cell Carcinoma × toripalimab × Clear all
NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

Sichuan University

Phase NA Not yet recruiting
98 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡